KRAS and non-small cell lung carcinoma: Based on these results, the phase 3 JUNIPER clinical trial was designed, in which previously-treated patients with advanced NSCLC with a KRAS mutation in codon 12 or 13 were randomized to receive either abemaciclib or erlotinib as second-line treatment in patients with NSCLC with a KRAS mutation [49].